source
- FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High CholesterolThe U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduc…fda press · 13d ago↗ source
- India’s life sciences sector at turning point for innovation: ReportStructural gaps in areas including clinical execution and funding limit India’s ability to scale up innovation, according to a report from Boston Consulting Group and HealthKois.BioSpace · 13d ago↗ source
- GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 failCamlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.